Vetr Inc. disclosed Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), hiking its stock price target to $14.00 earlier today
- Updated: September 19, 2016
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) had its target price bumped up to $14 by Vetr Inc. in an issued report released 9/19/2016. The new target price suggests a potential upside of 0.09% from the bussiness’ last stock close price.
On Wednesday September 7 2016, Northland Securities released a statement for Sucampo Pharmaceuticals, Inc.(NASDAQ:SCMP) upped the target price from $0.00 to $15.00 that indicated a possible upside of 0.26%.
Boasting a price of $12.79, Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) traded 3.73% higher on the day. With the last close up 12.42% relative to the two hundred day average, compared to the S&P 500 which has fallen -0.01% over the same time period. SCMP has recorded a 50-day moving average of $11.73 and two hundred day average of $11.38. 360,580 shares of SCMP exchanged hands, up from ann average trading volume of 341,452
Sucampo Pharmaceuticals, Inc. has a price-earnings of 45 with a one-year low of $9.59 and a 52 week high of $26.96. The company’s total market value is presently $0.0.
In addition to Vetr Inc. reporting it’s price target, a total of 9 analysts have reported on the company. The one year target price is $20.67 with one analyst rating the company a strong buy, four firms rating the company a buy, four firms rating the stock a hold, 0 rating the stock to underperform, and lastly 0 firmsrating the company as sell.
More About Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom. It offers AMITIZA for the treatment of constipation and RESCULA for the lowering of intraocular pressure (IOP). Its products under development include cobiprostone, and RTU-1096 and RTU-009.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.